56 citations,
August 2019 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.
21 citations,
January 2016 in “Skin appendage disorders” Alfredo Rebora suggested a new, easier way to classify hair loss in Telogen Effluvium, adding a type possibly related to autoimmune diseases.
5 citations,
February 2014 in “PubMed” Hair loss in Telogen effluvium is often chronic, linked to stress, and lacks a confirmed treatment, but topical corticosteroids may be used.
1 citations,
August 2021 in “Internal Medicine Journal” After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.
70 citations,
February 2015 in “Expert Opinion on Drug Discovery” Topical drugs and near-infrared light therapy show potential for treating alopecia.